EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Hemorrhage - Pipeline Review, H1 2017

  • ID: 4115124
  • Report
  • March 2017
  • 31 pages
  • Global Markets Direct
1 of 4
Hemorrhage - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hemorrhage - Pipeline Review, H1 2017, provides an overview of the Hemorrhage (Hematological Disorders) pipeline landscape.

Hemorrhage is a disease which results in excessive bleeding. Causes of hemorrhage include liver disease, bleeding disorder, high blood pressure, injury and aneurysm. Symptoms include nausea or vomiting, difficulty swallowing, loss of coordination, loss of consciousness, severe headache and tingling or numbness.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hemorrhage - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Phase 0 and Preclinical stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Hemorrhage (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemorrhage (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemorrhage (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemorrhage (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemorrhage (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemorrhage (Hematological Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemorrhage (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemorrhage (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Hemorrhage - Overview

Hemorrhage - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemorrhage - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemorrhage - Companies Involved in Therapeutics Development

Cellphire Inc

Haemostatix Ltd

Savara Inc

Hemorrhage - Drug Profiles

coagulation factor VIIa (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethinylestradiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PeproStat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Postpartum Hemorrhage - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombosomes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemorrhage - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Hemorrhage, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hemorrhage - Pipeline by Cellphire Inc, H1

Hemorrhage - Pipeline by Haemostatix Ltd, H1

Hemorrhage - Pipeline by Savara Inc, H1

Hemorrhage - Dormant Projects, H1

List of Figures:

Number of Products under Development for Hemorrhage, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Cellphire Inc
  • Haemostatix Ltd
  • Savara Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll